Welcome to today's Investors Symposium on Technical Analysis. I'm your host, Respert24 and I have (inaudible) number of years investing, successfully using a proprietary technical analysis approach to investing. Today we discuss Cytodyn and gaps. So with no further ado, please welcome me.
Gaps. (music starts building in the background)
The little investors engine tool that could. The tool straw that broke the camel's back. The tool for what ails you.
GAPS! (insert fireworks gif here)
Enough preamble. Let's begin. I have been tracking the gaps, guys. And gals. It's been crazy watching gaps get filled.
The gaps are my muse and I will share this knowledge with you tonight.
It's not widely known but if you stare directly into the gap you can read its soul. You can get a feel for it's gappiness. The depths of its gaptitude. The girth, if you will, of the outer portion of the gap. The outie. Some gaps are outies and some gaps are innies. You often can't tell until the gap is birthed and a death cross forms. Then you get a feel for both the angle and the dangle of the gap. It's science, really.
Once, I was charting a stock I had been following for quite some time. It was a company focused on overactive bladder. Huge gaps. Runny gaps. And I made the mistake of getting too deep in the gaps. I was up to my armpits. Wet with gaps, if you will. Lousy with gaps. But for the grace of god I was able to chart my way out. I mapped a course and charted myself clear, gaps clenching shut in my wake like pelvic muscles desperately holding in pee.
Gaps can inform just as gaps can overwhelm.
So it is with a tremendous amount of gap experience that I tell you what my gaps are showing right now. The quips, if you will, from my gaps. The gap headlines, you could say.
My gaptions.
They're telling me to buy if I can.
(They're understandably courteous in their recommendations because they know I'm not always flush with cash)
They also say to hold if I can't buy.
(They're understandably obvious in their explanation because I'm often a bottle of wine into the evening before we gap it up. One can never be too clear when discussing life or death investments)
They, lastly, are also telling me that the numbers don't add up.
The gap isn't matching the confidence of our last group of investors who seem to think that $10/share or above is what this puppy is capable of. They aren't dummies. The puppy is CYDY. Please try to keep up.
It isn't matching the science, either. The science that clearly shows Leronlimab to be a superior option to anything approved and, so far, anything else with any sort of trial data available. Science isn't a dummy no matter how much a certain politician tries to undermine it and a certain agency tries to ignore it.
Finally, it's clear that the price range of shares today is telling us something. Are we willing to listen?
(Respert24 drops the mic after such a deep final thought, gives a Sammy Sosa-style salute to the heavens, then throws something to the floor that explodes in a cloud of smoke. As it dissipates we see that Respert24 is no longer there. Gone. Not unlike your shares if you don't heed the gaps.)
#TechnicalAnalysis
Gaps. (music starts building in the background)
The little investors engine tool that could. The tool straw that broke the camel's back. The tool for what ails you.
GAPS! (insert fireworks gif here)
Enough preamble. Let's begin. I have been tracking the gaps, guys. And gals. It's been crazy watching gaps get filled.
The gaps are my muse and I will share this knowledge with you tonight.
It's not widely known but if you stare directly into the gap you can read its soul. You can get a feel for it's gappiness. The depths of its gaptitude. The girth, if you will, of the outer portion of the gap. The outie. Some gaps are outies and some gaps are innies. You often can't tell until the gap is birthed and a death cross forms. Then you get a feel for both the angle and the dangle of the gap. It's science, really.
Once, I was charting a stock I had been following for quite some time. It was a company focused on overactive bladder. Huge gaps. Runny gaps. And I made the mistake of getting too deep in the gaps. I was up to my armpits. Wet with gaps, if you will. Lousy with gaps. But for the grace of god I was able to chart my way out. I mapped a course and charted myself clear, gaps clenching shut in my wake like pelvic muscles desperately holding in pee.
Gaps can inform just as gaps can overwhelm.
So it is with a tremendous amount of gap experience that I tell you what my gaps are showing right now. The quips, if you will, from my gaps. The gap headlines, you could say.
My gaptions.
They're telling me to buy if I can.
(They're understandably courteous in their recommendations because they know I'm not always flush with cash)
They also say to hold if I can't buy.
(They're understandably obvious in their explanation because I'm often a bottle of wine into the evening before we gap it up. One can never be too clear when discussing life or death investments)
They, lastly, are also telling me that the numbers don't add up.
The gap isn't matching the confidence of our last group of investors who seem to think that $10/share or above is what this puppy is capable of. They aren't dummies. The puppy is CYDY. Please try to keep up.
It isn't matching the science, either. The science that clearly shows Leronlimab to be a superior option to anything approved and, so far, anything else with any sort of trial data available. Science isn't a dummy no matter how much a certain politician tries to undermine it and a certain agency tries to ignore it.
Finally, it's clear that the price range of shares today is telling us something. Are we willing to listen?
(Respert24 drops the mic after such a deep final thought, gives a Sammy Sosa-style salute to the heavens, then throws something to the floor that explodes in a cloud of smoke. As it dissipates we see that Respert24 is no longer there. Gone. Not unlike your shares if you don't heed the gaps.)
#TechnicalAnalysis
16
